Filed with ASX · · 9 pages · English
CLEO Diagnostics Ltd has released its quarterly activities and cash flow report for the September quarter, detailing significant advancements in its ovarian cancer diagnostic programs. The report highlights the progress of analytical validation following the receipt of test kits and the engagement of a U.S. laboratory for clinical validation testing. Additionally, the company has filed two new provisional patents related to its biomarker technology aimed at early detection of ovarian cancer. CLEO Diagnostics is well-funded to meet its clinical and regulatory milestones, with a cash balance reported at the end of the quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement September 2026 Quarterly Activities Report Highlights ? Analytical Validation in progress following receipt of ?rst batch of test kits ? Statement of Work executed with CLIA-certi?ed U.S. laboratory, Asuragen, to undertake the pivotal Clinical Validation testing program ? Screening...
